D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 138 SEK -0.72% Market Closed
Market Cap: 2.3B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Relative Value

The Relative Value of one DVYSR stock under the Base Case scenario is 184.02 SEK. Compared to the current market price of 138 SEK, Devyser Diagnostics AB is Undervalued by 25%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DVYSR Relative Value
Base Case
184.02 SEK
Undervaluation 25%
Relative Value
Price
D
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
10
vs Industry
47
Median 3Y
9.2
Median 5Y
9.2
Industry
8.1
Forward
9.9
vs History
vs Industry
Median 3Y
-29.7
Median 5Y
-29.7
Industry
23
Forward
-35.3
vs History
vs Industry
Median 3Y
-29.3
Median 5Y
-29.3
Industry
23.4
vs History
vs Industry
Median 3Y
-16
Median 5Y
-16
Industry
27.3
vs History
2
vs Industry
19
Median 3Y
3
Median 5Y
3
Industry
2.6
vs History
2
vs Industry
41
Median 3Y
6.9
Median 5Y
6.9
Industry
8.1
Forward
9.4
vs History
2
vs Industry
37
Median 3Y
8.4
Median 5Y
8.4
Industry
9.6
vs History
vs Industry
Median 3Y
-27.4
Median 5Y
-27.4
Industry
4.3
Forward
-51
vs History
vs Industry
Median 3Y
-20.8
Median 5Y
-20.8
Industry
3.8
Forward
-32.9
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-20.5
Industry
6
vs History
vs Industry
Median 3Y
-12.6
Median 5Y
-12.6
Industry
3.8
vs History
24
vs Industry
28
Median 3Y
6.3
Median 5Y
6.3
Industry
4.8

Multiples Across Competitors

DVYSR Competitors Multiples
Devyser Diagnostics AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Devyser Diagnostics AB
STO:DVYSR
2.3B SEK 11.6 -32.1 -41 -28
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 380 957.8 -177 666.1 -215 743.3 -213 281.4
US
Abbvie Inc
NYSE:ABBV
302.3B USD 5.4 59.5 14.9 22.9
US
Amgen Inc
NASDAQ:AMGN
160.6B USD 4.9 38 17.7 33.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.3B USD 11.9 -263.2 26.7 28
US
Gilead Sciences Inc
NASDAQ:GILD
118.3B USD 4.2 939 10.4 10.4
US
Epizyme Inc
F:EPE
94.1B EUR 1 884.6 -480.9 -523.7 -509.7
AU
CSL Ltd
ASX:CSL
138.5B AUD 6.1 34.3 21.1 26.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
90.4B USD 6.5 19.4 17.9 19.9
US
Seagen Inc
F:SGT
39.3B EUR 18.2 -55.7 -59.8 -54
NL
argenx SE
XBRU:ARGX
33.4B EUR 18.2 -127.9 -102.8 -74.9
P/E Multiple
Earnings Growth
SE
D
Devyser Diagnostics AB
STO:DVYSR
Average P/E: 218
Negative Multiple: -32.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -177 666.1 N/A
US
Abbvie Inc
NYSE:ABBV
59.5
412%
US
Amgen Inc
NASDAQ:AMGN
38
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -263.2
42%
US
Gilead Sciences Inc
NASDAQ:GILD
939
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -480.9 N/A
AU
CSL Ltd
ASX:CSL
34.3
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -127.9 N/A
EV/EBITDA Multiple
EBITDA Growth
SE
D
Devyser Diagnostics AB
STO:DVYSR
Average EV/EBITDA: 18.1
Negative Multiple: -41
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -215 743.3 N/A
US
Abbvie Inc
NYSE:ABBV
14.9
28%
US
Amgen Inc
NASDAQ:AMGN
17.7
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -523.7 N/A
AU
CSL Ltd
ASX:CSL
21.1
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -102.8 N/A
EV/EBIT Multiple
EBIT Growth
SE
D
Devyser Diagnostics AB
STO:DVYSR
Average EV/EBIT: 23.5
Negative Multiple: -28
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -213 281.4 N/A
US
Abbvie Inc
NYSE:ABBV
22.9
88%
US
Amgen Inc
NASDAQ:AMGN
33.4
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -509.7 N/A
AU
CSL Ltd
ASX:CSL
26.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -74.9 N/A

See Also

Discover More
Back to Top